This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Investigating the potential of Outlook's LYTENAVA (ONS-5010) as a treatment for Wet AMD
Ticker(s): OTLKWho's the expert?
Institution: Virginia Eye Consultants
- Board-certified ophthalmologist who is fellowship trained in Vitreo-Retinal surgery.
- Currently manages 300 patients with Wet AMD.
- Clinical interests and research includes: diagnosis and treatment of retinal diseases, age-related macular degeneration, diabetic retinopathy, uveitis, retinal detachments, and vitreomacular adhesion.
Interview GoalTo discuss the standard of care and the potential of ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) being developed by Outlook Therapeutics.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
